Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCT2013190001
JPRN-jRCT2013190001
Recruiting
未知

ong-term follow-up study of patients who have previouslybeen exposed to UCART19 (allogeneic engineered T-cellsexpressing a lentiviral-based anti-CD19 chimeric antigenreceptor) - LTFU study

clinical operation department International center for therapeutic research0 sites200 target enrollmentApril 28, 2019
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
clinical operation department International center for therapeutic research
Enrollment
200
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 28, 2019
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
clinical operation department International center for therapeutic research

Eligibility Criteria

Inclusion Criteria

  • •All patients dosed with UCART19 must be enrolled in the long\-term follow up study after the completion of the parent study.

Exclusion Criteria

  • •No exclusion criteria for this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19Advanced lymphoid malignanciesMedDRA version: 20.0Level: LLTClassification code 10060390Term: Leukaemia lymphoblastic acuteSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-000297-38-BEInstitut de Recherches Internationales Servier (I.R.I.S)200
Active, not recruiting
Phase 1
A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19Advanced lymphoid malignanciesMedDRA version: 20.0Level: LLTClassification code 10060390Term: Leukaemia lymphoblastic acuteSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-000297-38-FRInstitut de Recherches Internationales Servier (I.R.I.S)200
Active, not recruiting
Phase 1
A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19Advanced lymphoid malignanciesMedDRA version: 20.0 Level: LLT Classification code 10060390 Term: Leukaemia lymphoblastic acute System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-000297-38-ESInstitut de Recherches Internationales Servier (I.R.I.S)200
Active, not recruiting
Phase 1
A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19 or ALLO-501Advanced lymphoid malignanciesMedDRA version: 21.0Level: LLTClassification code 10060390Term: Leukaemia lymphoblastic acuteSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10008958Term: Chronic lymphocytic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-000297-38-GBInstitut de Recherches Internationales Servier (I.R.I.S)200
Active, not recruiting
Phase 1
ong-term follow-up of patients previously treated with autologous T cells genetically modified with viral vectors.
CTIS2024-511684-28-00Autolus Limited111